TP53-Associated Pediatric Malignancies.

Although the majority of pediatric malignancies express wild-type p53, it is well established that germline TP53 mutations or functional inactivation of this pathway by other means contribute to childhood cancer. Epidemiology studies have revealed the existence of diverse inherited mutant TP53 alleles that display different levels of tumor suppressor activity, which correlate with cancer risk in terms of penetrance, age of onset, and tumor types. In this monograph, the authors describe those childhood cancers associated with functional inactivation of TP53 focusing on adrenocortical carcinoma as a model for tissues that are highly sensitive to loss of p53 activity.

[1]  Joakim Lundeberg,et al.  Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. , 2005, Surgery.

[2]  W P Bennett,et al.  Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer , 1999, The Journal of pathology.

[3]  E. Lalli,et al.  High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. , 2008, Cancer genetics and cytogenetics.

[4]  D. Evans,et al.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome , 1998, Oncogene.

[5]  T. Davison,et al.  Characterization of the oligomerization defects of two p53 mutants found in families with Li–Fraumeni and Li–Fraumeni-like syndrome , 1998, Oncogene.

[6]  D. Evans,et al.  Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. , 1999, American journal of human genetics.

[7]  C. Bonaïti‐pellié,et al.  Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.

[8]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[9]  E. Pinto,et al.  Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. , 2004, Arquivos brasileiros de endocrinologia e metabologia.

[10]  S. Shurtleff,et al.  Association of the germline TP53 R337H mutation with breast cancer in southern Brazil , 2008, BMC Cancer.

[11]  L. Strong,et al.  Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. , 1992, American journal of human genetics.

[12]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[13]  J. A. Yunes,et al.  Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil , 2011, Cancer.

[14]  E. Lalli,et al.  Gene expression profiling of childhood adrenocortical tumors. , 2007, Cancer research.

[15]  G. Wahl,et al.  Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.

[16]  E. Lalli,et al.  SF-1 overexpression in childhood adrenocortical tumours. , 2006, European journal of cancer.

[17]  Wensheng Yan,et al.  Characterization of Functional Domains Necessary for Mutant p53 Gain of Function*♦ , 2010, The Journal of Biological Chemistry.

[18]  V. Rotter,et al.  Transcription regulation by mutant p53 , 2007, Oncogene.

[19]  G. Zambetti,et al.  The p53 mutation “gradient effect” and its clinical implications , 2007, Journal of cellular physiology.

[20]  A. Bradley,et al.  Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[22]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[23]  S. Shurtleff,et al.  Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor , 2010, Familial Cancer.

[24]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[25]  E. Pinto,et al.  Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. , 2005, The Journal of clinical endocrinology and metabolism.

[26]  E. Pinto,et al.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  P. Boffetta,et al.  Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil , 2006, Pediatric blood & cancer.

[28]  J. Varley.  Germline TP53 mutations and Li‐Fraumeni syndrome , 2003, Human mutation.

[29]  R. Ribeiro,et al.  Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. , 2006, Cancer research.

[30]  R. Ribeiro,et al.  A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer , 2002, Nature Structural Biology.

[31]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[32]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[33]  C. Stratakis,et al.  Inhibin α-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers , 2004, Journal of Medical Genetics.

[34]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[35]  Paul G Gauger,et al.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. , 2003, The American journal of pathology.

[36]  E. Lalli,et al.  Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. , 2007, Molecular endocrinology.

[37]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[38]  C. Rodríguez-Galindo,et al.  Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Latorre,et al.  Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters. , 2007, Clinics.

[40]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[41]  C. Antunes,et al.  Color and genomic ancestry in Brazilians , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  V. Han,et al.  Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution. , 1988, The Journal of clinical endocrinology and metabolism.

[43]  R. Ribeiro,et al.  Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma , 2008, Journal of Medical Genetics.

[44]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[45]  C. Nies,et al.  Adrenal Involvement in Multiple Endocrine Neoplasia Type 1 , 2002, World Journal of Surgery.

[46]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[47]  C. Teinturier,et al.  Clinical and prognostic aspects of adrenocortical neoplasms in childhood. , 1999, Medical and pediatric oncology.

[48]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[49]  C. Portwine,et al.  High frequency of germline p53 mutations in childhood adrenocortical cancer. , 1994, Journal of the National Cancer Institute.

[50]  P. Boffetta,et al.  Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation , 2005, Journal of Medical Genetics.

[51]  T. Jacks,et al.  Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[53]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Stratakis,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Comparative Genomic Hybridization Analysis of Adrenocortical Tumors of Childhood* , 2022 .

[56]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[57]  R. Camplejohn,et al.  Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members , 1998, Oncogene.

[58]  S. Friend,et al.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[60]  B. Schimmer,et al.  Steroidogenic factor 1: a key determinant of endocrine development and function. , 1997, Endocrine reviews.

[61]  L. Strong,et al.  The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. , 1992, American journal of epidemiology.

[62]  R. Eeles,et al.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.

[63]  C. Stratakis,et al.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. Lalli,et al.  Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[65]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[66]  J. Fraumeni,et al.  Cancer epidemiology and prevention. , 2006 .